[Clinical experience with a new vasotherapeutic agent in diseases of the fundus (author's transl)].
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D001157:Arterial Occlusive Diseases / Q000188:drug therapy; D001205:Ascorbic Acid / Q000627:therapeutic use; D002561:Cerebrovascular Disorders / Q000188:drug therapy; D002648:Child; D002825:Chorioretinitis / Q000188:drug therapy; D004487:Edema / Q000188:drug therapy; D005260:Female; D006801:Humans; D007659:Ketones / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D012161:Retinal Artery; D012162:Retinal Degeneration / Q000188:drug therapy; D012164:Retinal Diseases / Q000188:drug therapy*; D012171:Retinal Vessels; D012431:Rutin / Q000627:therapeutic use; D014803:Vitamin B Complex / Q000627:therapeutic use; D014970:Xanthines / Q000627:therapeutic use*
D000305:Adrenal Cortex Hormones; D007659:Ketones; D014970:Xanthines; D014803:Vitamin B Complex; D012431:Rutin; D001205:Ascorbic Acid
Klinische Erfahrungen mit einem neuen Vasotherapeutikum bei Erkrankungen des Augenhintergrundes.